After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration

Posted inBiotechnology

After signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaboration and licensing agreement.